2020 Radiology / Imaging Guide - 24

IV Solution

HEADER

Your IV solution
0.9% Sodium Chloride Injection, USP, in

plastic container

Non-PVC, non-DEHP, and non-latex flexible container.
The solution is only in contact with polypropylene, highly compatible material.
Designed for safe and easy handling: rounded upper and lower corners and integrated eyelet support.
High sealing resistance to pressure cuffs responding satisfactorily to 400 mmHg pressure for 72 hours.
s.
Totally collapsible, lightweight, and transparent.
Safe attachment of the infusion set thanks to the outlet port internal membrane.
No parts of the cover have to be removed to access the outlet port.
Transparent overwrap to allow visual inspection with peelable opening system.
HSI Item #

(133-3120)
(133-3123)
(133-3124)
(131-0140)
(133-3143)

Description
0.9% Sodium Chloride Injection, USP, 50 mL
0.9% Sodium Chloride Injection, USP, 100 mL
0.9% Sodium Chloride Injection, USP, 250 mL
0.9% Sodium Chloride Injection, USP, 500 mL
0.9% Sodium Chloride Injection, USP, 1000 mL

Packaging
115/case
70/case
28/case
20/case
10/case

Please see Important Safety Information
below and refer to accompanying
full Prescribing Information for
0.9% Sodium Chloride Injection, USP.

Important Safety Information
Sodium Chloride Injection, USP is indicated as a source of water and electrolytes.
0.9% Sodium Chloride Injection, USP is also indicated for use as a priming solution in hemodialysis procedures.

Contraindications
None known.
Warnings and Precautions
Hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, urticaria, rash, and pruritus have been reported with 0.9% Sodium Chloride Injection,
USP. Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction
develop, such as tachycardia, chest pain, dyspnea and flushing. Depending on the volume and rate of infusion, the intravenous administration of Sodium Chloride Injection,
USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte
concentrations, overhydration/hypervolemia, congested states, pulmonary edema, or
acid-base imbalance. Monitor changes in fluid balance, electrolyte concentrations, and
acid base balance during prolonged parenteral therapy or whenever the condition of
the patient or the rate of administration warrants such evaluation. Administer 0.9%
Sodium Chloride Injection, USP with particular caution to patients with or at risk for
hypernatremia, hyperchloremia, or metabolic acidosis. Administer Sodium Chloride
Injection, USP with particular caution to patients with or at risk for hypervolemia or
with conditions that may cause sodium retention, fluid overload and edema, such as
patients with primary hyperaldosteronism or secondary hyperaldosteronism (eg, associated with hypertension, congestive heart failure, liver disease [including cirrhosis],
renal disease [including renal artery stenosis, nephrosclerosis], or pre-eclampsia). Administer Sodium Chloride Injection, USP with particular caution to patients with severe
renal impairment. Do not connect flexible plastic containers in series in order to avoid
air embolism due to possible residual air contained in the primary container. Such use
could result in air embolism due to residual air being drawn from the primary container
before administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow
rates can result in air embolism if the residual air in the container is not fully evacuated
prior to administration. Use of a vented intravenous administration set with the vent in
the open position could result in air embolism. Vented intravenous administration sets
with the vent in the open position should not be used with flexible plastic containers.

Rapid correction of hypo- and hypernatremia is potentially dangerous (risk of serious
neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in intravenous fluid therapy. Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients treated with
drugs that may increase the risk of sodium and fluid retention, such as corticosteroids.
Renal sodium and lithium clearance may be increased during administration of 0.9%
Sodium Chloride Injection, USP. Administration of 0.9% Sodium Chloride Injection,
USP may result in decreased lithium levels.
Use in Specific Populations
Sodium Chloride Injection, USP should be given during pregnancy only if the potential
benefit justifies the potential risk to the fetus. Because many drugs are present in
human milk, caution should be exercised when Sodium Chloride Injection, USP is
administered to a nursing woman. Plasma electrolyte concentrations should be closely
monitored in the pediatric population as this population may have impaired ability to
regulate fluids and electrolytes. This drug is known to be substantially excreted by
the kidney, and the risk of toxic reactions to this drug may be greater in patients with
impaired renal function. Because elderly patients are more likely to have decreased
renal function, care should be taken in dose selection, and it may be useful to monitor
renal function.
Adverse Reactions
The following adverse reactions have been reported in the post-marketing experience
during use of 0.9% Sodium Chloride Injection, USP and include the following: hypersensitivity/infusion reactions, including hypotension, pyrexia, tremor, chills, ur ticaria,
rash, and pruritus. Also reported are infusion site reactions, such as infusion site erythema, injection site streaking, burning sensation, and infusion site urticarial.
Please see accompanying full Prescribing Information for
0.9% Sodium Chloride Injection, USP.

Manufactured by:
Laboratorios Grifols S.A.
Calle Marte nº4 Polígono Industrial Los Llanos
30565 Las Torres de Cotillas, Murcia - SPAIN
www.grifols.com

henryschein.com/medical

20MS5434

http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1333120%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dradiology-imaging2020%26utm_term%3D1333120 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1333123%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dradiology-imaging2020%26utm_term%3D1333123 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1333124%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dradiology-imaging2020%26utm_term%3D1333124 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1310140%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dradiology-imaging2020%26utm_term%3D1310140 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx%3Fproductid%3D1333143%26CatalogName%3DMEDICAL%26utm_source%3DMedical%26utm_medium%3DNxtbook%26utm_campaign%3Dradiology-imaging2020%26utm_term%3D1333143 http://www.grifols.com http://www.henryschein.com/medical

2020 Radiology / Imaging Guide

Table of Contents for the Digital Edition of 2020 Radiology / Imaging Guide